Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
about
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12Regulating the immune system via IL-15 transpresentationCrystal Structure of the interleukin-15.interleukin-15 receptor alpha complex: insights into trans and cis presentationThe shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapyIntramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cellsEngulfing tumors with synthetic extracellular matrices for cancer immunotherapyLoss of IL-15 receptor α alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles.Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma.Novel human interleukin-15 agonistsNew insights into the regulation of T cells by gamma(c) family cytokinesInterleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cellsDifferential requirement for CCR4 and CCR7 during the development of innate and adaptive αβT cells in the adult thymus.A defective Il15 allele underlies the deficiency in natural killer cell activity in nonobese diabetic mice.Thymic and peripheral microenvironments differentially mediate development and maturation of iNKT cells by IL-15 transpresentation.Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.IL-15 participates in the respiratory innate immune response to influenza virus infectionInterleukin-15 treatment induces weight loss independent of lymphocytes.Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activityMature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes.Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cisIL-2 complex treatment can protect naive mice from bacterial and viral infection.Self-specific CD8+ T cells maintain a semi-naive state following lymphopenia-induced proliferation.Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapyInterleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune moleculesA role for IL-15 in the migration of effector CD8 T cells to the lung airways following influenza infection.Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo.Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cellsDevelopment of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Rα.Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1Combined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing Ag-specific CTL responses.Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses.MHC class I and TCR avidity control the CD8 T cell response to IL-15/IL-15Rα complex.The natural killer cell dysfunction of aged mice is due to the bone marrow stroma and is not restored by IL-15/IL-15Rα treatment.Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization.Soluble interleukin-15 complexes are generated in vivo by type I interferon dependent and independent pathwaysIRF-1 promotes liver transplant ischemia/reperfusion injury via hepatocyte IL-15/IL-15Rα production
P2860
Q26796316-70B95F48-B445-431F-9246-5BBD1379B365Q26825247-24B30256-64F5-473F-A5B7-CC7D5F411D20Q27648832-462E4840-9D35-44D1-8465-F1E306253C43Q28088784-EB62A20C-4C66-48EF-A126-78E7A5D21FB4Q28652428-A979DBD7-6B9A-4F90-A010-4228F3FDBD03Q28749647-F5EDCD67-F61A-4E98-83BC-21E096CF6729Q30503154-FD5B383C-12FC-4584-987E-70564073CBF7Q33494834-45AB969E-D5A4-420D-83E1-DC37ADDD9BE5Q33623266-B55E9A4A-5D8D-4657-A927-6410AFF405C0Q33623326-EDED72E4-1A8B-4F56-B52B-815B96527857Q33638464-A142276E-FCA4-4B1A-B725-7D90E8A82F4FQ33711371-9264E05B-0A73-41B0-811D-31B96E3C3766Q33767707-0714EBFC-DEFE-4AEF-913D-3FF7598D4CE7Q33927143-C046FD16-2CD3-401C-93E8-BC83A1F16C35Q33927289-EB7D85DC-ABB2-48FF-BA9D-B4A577F4A471Q34193542-6A8509A1-0CED-4EB5-BFCA-49C7B0826BAAQ34223872-7EFD07BE-4C0B-4013-AC0E-EE548C156B78Q34280059-E3002943-223E-4902-9F52-07EBD08309E0Q34328178-46BDCADF-7E5A-4791-883A-A19BE423C4AAQ34351517-9ED41B97-61B7-447B-8F07-8911ED42763EQ34411539-D8F12D61-B404-4F74-A38C-656BA69EC1FFQ34415755-6EBEFBA0-838F-4B02-BE07-9AA966958AC3Q34470815-3E374AC2-F184-4FC2-A1E6-2A999EB315F0Q34470833-0052D482-4E70-40B8-8C79-C4066475CB66Q34533728-DD3D5FF5-7D1A-40D8-B34B-AD9A0DA23C29Q34626998-46341014-4F89-4089-A2E2-4C6F38B71AA3Q34632137-A872995C-66F3-4E3D-A842-E1FF28943093Q34708192-C3A228CC-F4A1-42F9-8B83-2D3BF0481670Q34794353-1EB15C91-2F91-4AFA-ADFA-700A6885F862Q34877332-1613566A-00A8-484B-A0D9-B129E498ECFDQ34924364-B3784153-72FB-479C-963C-34D4294C6488Q35060701-6BF113A2-5020-4B03-ACF0-453BCC8BC37FQ35082617-553D8AC8-0CDC-48DD-9BAB-5558590D6AD6Q35095630-E9DAF766-25D2-472A-924A-AF6C0F5C7B23Q35147335-9A7A9CBE-19EC-4925-B7C5-82538D5E3B4DQ35192116-9137BFD8-04CB-4717-BD96-597BDCC69E2BQ35212373-54ECAD02-224F-4387-AC12-312DFDEC7E76Q35566748-9666A63C-C2C5-46A3-A6BF-0E8CF9734386Q35574404-D374E247-23F6-4E33-BDEC-C0B687EFB8ADQ35691185-AEB52C09-8D0F-4953-B3E9-BB84A91A665B
P2860
Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
@ast
Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
@en
type
label
Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
@ast
Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
@en
prefLabel
Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
@ast
Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
@en
P2093
P2860
P1476
Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
@en
P2093
Kimberly S Schluns
Leo Lefrançois
Thomas A Stoklasek
P2860
P304
P356
10.4049/JIMMUNOL.177.9.6072
P407
P577
2006-11-01T00:00:00Z